Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
riTUXimab
riTUXimab
- Restricted Utilize most cost-effective product for FDA-approved indications
Last updated: Apr. 30, 2026
For Updated Formulary Preferred Products (Inpatient and Outpatient): Preferred Products for Select Agents
Drug reviewed for Outpatient Infusion (updated May 7, 2021)
Truxima, Riabni, and Ruxience are considered therapeutically equivalent to Rituxan for FDA approved indications and literature supported off-label uses. The most cost effective product will be used in a specific setting, time period, or patient case.
For non-oncologic indications including, but not limited to, rheumatology, nephrology, and benign hematology, a second clinical verification by the Oncology Clinical Specialists is not required. These orders can be verified by the covering pharmacist as clinically appropriate. For more information: Rituximab for Non-Malignant Indications
Outpatient riTUXimab cycle 2+ rapid infusion protocol available for adults.
RiTUXimab cycle 2+ rapid infusion (adults)
Reviewed: 23 July 2019 (Truxima). October 22, 2019, 24 March 2020 (Ruxience), April 2026 (Riabni)